• Explore /
  • Poster
  • / Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).

Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A randomized phase 2 study (GOAL, Spanish Lung Cancer Group).

Abstract Poster

Authors

null

Rosario Garcia Campelo

Medical Oncology Service, University Hospital A Coruña (XXIAC-SERGAS), A Coruña, Spain

Rosario Garcia Campelo , Oscar Gerardo Arrieta Rodriguez , Bartomeu Massuti , Delvys Rodriguez-Abreu , Ana Laura Ortega Granados , Margarita Majem , David Vicente , Pilar Lianes , Joaquim Bosch-Barrera , Amelia Insa , Manuel Domine , Noemi Reguart , Maria Guirado , María Ángeles Sala , Sergio Vazquez-Estevez , Reyes Bernabe Caro , Ana Drozdowskyj , Ana Verdu , Niki Karachaliou , Rafael Rosell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01513174

Citation

J Clin Oncol 36, 2018 (suppl; abstr 9012)

DOI

10.1200/JCO.2018.36.15_suppl.9012

Abstract #

9012

Poster Bd #

335

Abstract Disclosures

Similar Posters

First Author: Rosario Garcia Campelo

First Author: Bartomeu Massuti

First Author: Youngjoo Lee

First Author: Chee Lee